INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Option exerciseVerified data

Yan Ming reported CTKB

Director, CHIEF TECHNOLOGY OFFICER · Cytek Biosciences, Inc. · Common Stock

Side
M
Value
—
Shares
6,162
Price
—
Executed
Nov 18, 2025
Disclosed
Nov 20, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 18 executedNov 20, 2025 disclosed

CTKB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 0.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CTKB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    57.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$33K
    7,062 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    13.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    5,525 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    14.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$7,010
    1,501 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    14.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    29.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    22.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$8,303
    1,778 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    22.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$16K
    3,463 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,320 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$25K
    5,401 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$6,286
    1,346 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,162 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001874041-25-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 18, 2025
    Published
    Nov 20, 2025
    Ingested by INSIDER
    Nov 5, 04:32 UTC
    Last re-read
    Nov 5, 04:32 UTC

    Extracted facts

    Filer
    Yan Ming
    Role
    Director, CHIEF TECHNOLOGY OFFICER
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Cytek Biosciences, Inc.
    Ticker
    CTKB
    Shares
    6,162
    Execution date (reported)
    Nov 18, 2025
    Owned after transaction
    6.07M shares
    Days from execution to publication
    2

    What this establishes

    Yan Ming filed this Form 4 reporting a option exercise of CTKB on Nov 18, 2025. It became public on Nov 20, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF TECHNOLOGY OFFICER
    Yan Mingcik:0001874041
    Issuer
    Cytek Biosciences, Inc.cik:0001831915

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.